Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$59.91
-1.3%		$57.89
$49.26
▼
$66.28
$11.74B0.241.58 million shs1.68 million shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$78.91
+1.4%		$73.30
$40.00
▼
$99.50
$2.97B1363,586 shs272,304 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$514.12
+1.3%		$515.17
$331.00
▼
$615.00
$11.73B-1.01390,014 shs349,484 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$13.53
-1.7%		$14.44
$12.25
▼
$30.05
$10.98B-1.233.69 million shs3.15 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-1.33%-2.38%+1.91%+10.70%-3.26%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
+1.43%+7.11%+2.47%+16.85%+29.72%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+1.29%-5.99%-2.90%-3.88%+51.70%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-1.67%+5.70%-15.07%-21.11%-53.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$59.91
-1.3%		$57.89
$49.26
▼
$66.28
$11.74B0.241.58 million shs1.68 million shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$78.91
+1.4%		$73.30
$40.00
▼
$99.50
$2.97B1363,586 shs272,304 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$514.12
+1.3%		$515.17
$331.00
▼
$615.00
$11.73B-1.01390,014 shs349,484 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$13.53
-1.7%		$14.44
$12.25
▼
$30.05
$10.98B-1.233.69 million shs3.15 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-1.33%-2.38%+1.91%+10.70%-3.26%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
+1.43%+7.11%+2.47%+16.85%+29.72%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+1.29%-5.99%-2.90%-3.88%+51.70%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-1.67%+5.70%-15.07%-21.11%-53.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.71
Moderate Buy$87.0945.37% Upside
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.73
Moderate Buy$104.4432.36% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$689.9334.20% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.44
Hold$26.1593.31% Upside

Current Analyst Ratings Breakdown

Latest IRON, BMRN, MDGL, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$605.00
8/3/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/29/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$578.00 ➝ $587.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/24/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$15.00
7/24/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$45.00 ➝ $38.00
7/24/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$40.00 ➝ $38.00
(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.24B3.57$2.82 per share21.28$31.68 per share1.89
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$16.88 per shareN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.39N/AN/A$22.67 per share22.68
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.79 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$1.3743.7310.640.468.29%6.50%5.07%8/6/2026 (Estimated)
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$212.18M-$6.58N/AN/AN/AN/A-37.17%-33.65%8/6/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A92.63N/A-25.32%-56.65%-25.53%N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest IRON, BMRN, MDGL, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.9450N/AN/AN/A$932.03 millionN/A
7/30/2026Q2 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.71-$1.54+$0.17-$1.54$1.00 millionN/A
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
5/6/2026Q1 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.61-$3.25+$0.36-$3.25$301.05 million$311.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.23
5.81
4.20
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.09
24.14
24.14
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.76%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.28 million191.97 millionOptionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3038.16 million36.73 millionNot Optionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110797.75 million131.63 millionOptionable

Recent News About These Companies

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
August 5 at 12:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/summit-therapeutics-further-expands-ivonescimab-110000142.html
Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock
August 4 at 8:15 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/long-ideas/26/08/60903683/jim-cramer-calls-summit-therapeutics-a-great-spec-recommends-buying-this-consumer-cyclical-stock?utm_source=snapi
The Manufacturers Life Insurance Company Has $11.24 Million Stake in Summit Therapeutics PLC $SMMT
August 4 at 5:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-has-1124-million-stake-in-summit-therapeutics-plc-smmt-2026-08-04/
Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Hold" by Analysts
August 3 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30938908
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts
August 3 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/summit-therapeutics-plc-nasdaqsmmt-receives-average-rating-of-hold-from-analysts-2026-08-03/
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches
July 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928818-summit-therapeutics-upgrading-to-hold-as-critical-approval-decision-approaches
What is HC Wainwright's Forecast for SMMT FY2026 Earnings?
July 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30931531
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)
July 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARGX-Q/pressreleases/3540467/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-and-argenx-se-argx/
What is HC Wainwright's Estimate for SMMT FY2026 Earnings?
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-estimate-for-smmt-fy2026-earnings-2026-07-29/
Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)
July 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HCA/pressreleases/3495946/analysts-conflicted-on-these-healthcare-names-hca-healthcare-hca-summit-therapeutics-smmt-and-neuphoria-therapeutics-neup/
Summit Therapeutics (NASDAQ:SMMT) Hits New 12-Month Low - Time to Sell?
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/summit-therapeutics-nasdaqsmmt-hits-new-12-month-low-time-to-sell-2026-07-28/
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
July 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-summit-therapeutics-inc-to-contact-law-firm-302834804.html
Summit Therapeutics Sees Unusually Large Options Volume (NASDAQ:SMMT)
July 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30921571
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data
July 24, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/smmt-stock-heads-for-third-straight-weekly-drop-analyst-tempers-expectations-from-initial-lung-cancer-trial-survival-data/ar-AA28CKKD
Traders Purchase High Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT)
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/traders-purchase-high-volume-of-call-options-on-summit-therapeutics-nasdaqsmmt-2026-07-24/
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down After Earnings Miss
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/summit-therapeutics-nasdaqsmmt-shares-gap-down-after-earnings-miss-2026-07-24/
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
July 24, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2960045/smmt-s-q2-loss-wider-than-expected-ivonescimab-development-in-focus?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2960045
Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain?
July 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/summit-therapeutics-smmt-updates-phase-021149384.html
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
July 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4925045-summit-therapeutics-inc-smmt-q2-2026-earnings-call-transcript
Summit Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation
July 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4925049-summit-therapeutics-inc-2026-q2-results-earnings-call-presentation
Summit Therapeutics Q2 Earnings Call Highlights
July 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/summit-therapeutics-q2-earnings-call-highlights-2026-07-23/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illuminated AV logo displayed on a riveted metal panel surrounded by cables and machinery components.
AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
By Jeffrey Neal Johnson | July 10, 2026
Autonomous military drone on a launch table with tactical map tablet and antennas, with other drones flying overhead.
Drone Stocks Are Down, But Defense Backlogs Tell a Different Story
By Thomas Hughes | July 8, 2026
AeroVironment logo with solar-powered drone above Earth, highlighting AVAV defense and unmanned systems growth.
AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
By Jeffrey Neal Johnson | July 21, 2026
Rio Tinto logo displayed over a mining site with excavators and a haul truck at sunset.
Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
By Chris Markoch | August 2, 2026
Military drone aircraft flying over a mountainous desert landscape at sunset.
3 Drone Stocks That Should Soar After the Summer Slump
By Chris Markoch | August 4, 2026
BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$59.91 -0.81 (-1.33%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$59.75 -0.16 (-0.27%)
As of 08/5/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$78.91 +1.11 (+1.43%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$78.84 -0.06 (-0.08%)
As of 08/5/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$514.12 +6.56 (+1.29%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$513.03 -1.09 (-0.21%)
As of 08/5/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$13.53 -0.23 (-1.67%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$13.60 +0.07 (+0.54%)
As of 08/5/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas